Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab ...Middle East

HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab )

Also on site :

• Amazon Has ‘Awesome’ $30 Arch Support Flip Flops on Sale for $12, and Reviewers Are ‘Stunned’ How Comfortable They Are
• Column: Adoption days are here at Pasadena Humane
• Amazon Is Selling the ‘Cutest’ $45 Vera Bradley Crossbody Bag for Just $21, and Shoppers Say It ‘Fits a Lot'